Miscellaneous Vascular Embolization Procedures
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and noncoverage for various vascular embolization procedures across Medicare Advantage and Commercial products for Blue Cross Blue Shield - Rhode Island.
A list of specific embolization indications considered medically necessary (19 items) was defined.
A list of procedures/conditions considered not covered or not medically necessary (13 items) was defined.
Prior authorization requirement for Medicare Advantage and recommendation for Commercial Products via web-based tool.
Coverage Criteria for Vascular Embolization Procedures
Medically necessary indications
Covered when ANY of the following indications are met:
For procedures or conditions not addressed in this policy, refer to the Medical Necessity policy in Related Policies.
Embolization for lower gastrointestinal bleeding
Covered when ONE of the following clinically supported indications is present:
Super-selective technique using coaxial microcatheters is recommended to reduce risk of bowel infarction.
Portal vein embolization (PVE) before hepatic resection
Covered when ALL of the following are met:
Hepatic surgeons generally wait approximately 3 to 6 weeks after PVE before undertaking resection.
Tumor embolization / preoperative devascularization
Covered when ALL of the following are met:
Considered medically necessary as a preoperative adjunct to reduce intraoperative bleeding.
Embolization for epistaxis and prostatic hematuria
Covered when ALL of the following are met:
Embolotherapy is an accepted alternative when conservative measures fail.
Evidence supports safety and effectiveness in this indication per cited study.
Embolization for endoleak management
Mixed coverage stance based on evidence sufficiency:
Reported results are favorable but broader conclusions depend on study quality.
Considered promising but not definitively supported.
Locoregional embolization for metastatic pancreatic cancer
Not covered outside clinical trials:
Systematic review authors recommend treatment only within experimental trials.
Other indications with insufficient evidence
Currently considered experimental/unproven:
High-quality randomized trials are needed.
Evidence is limited to small series or low-quality studies.
Middle meningeal artery embolization (MMAE) for chronic subdural hematoma (cSDH)
Mixed coverage stance dependent on indication and evidence:
Heterogeneous trial results warrant individualized consideration and further study.
Consider case-by-case and trial context given heterogenous evidence.
Indication-specific evidence summaries
Coverage stance is evidence-based and indication-specific; the document summarizes evidence but states insufficiency for net health benefit in several areas.
References include multiple 2025 meta-analyses and RCTs (MAGIC-MT, EMBOLISE, STEM).
Clinical importance of reduced blood loss/duration is uncertain.
Consider prior treatment history and retreatment risk when evaluating candidacy.
Use remains investigational pending higher-quality studies.
Encouraging early results but longer-term and larger studies needed.
This policy explicitly excludes vascular embolization procedures performed for the liver and for uterine fibroids. For those procedures, refer to the related Prior Authorization via Web-Based Tool for Procedures policy to determine prior authorization and coverage requirements.
Locoregional embolization for metastatic pancreatic ductal adenocarcinoma (mPDAC) and bariatric arterial embolization (BAE) are considered experimental/insufficient. The systematic review of locoregional treatments for mPDAC found that evidence is limited and recommended that locoregional treatment should not be provided outside the context of an experimental trial. For BAE, randomized and controlled trial data are small, single-center, and of uncertain clinical significance and durability; additional robust RCTs with long-term follow-up are needed before routine use can be recommended.
Overall, evidence is insufficient to determine net health benefit for several emerging embolization technologies and indications. Examples explicitly noted include HydroPearl microspheres for lower-extremity AVMs and hemorrhoidal embolization, paraumbilical vein coil embolization for hepatic encephalopathy, and multiple other applications (e.g., persistent sciatic artery embolization). Systematic reviews, small series, and limited RCTs suggest preliminary safety or efficacy signals in select settings, but higher-quality studies are required to establish effects on clinically meaningful outcomes.
Services that are determined to be not medically necessary or that fall into a non-covered benefit category are excluded from coverage. Providers should verify member benefits and eligibility prior to providing services. If a provider performs a service that is not covered or not medically necessary, the member must be informed and must agree in writing in advance to accept financial responsibility for the service; otherwise the provider may be at risk for claim denial and cannot charge the member.
The policy lists specific procedures considered not covered for Medicare Advantage and not medically necessary for Commercial Products because evidence is insufficient. These include (but are not limited to): coil embolization for LVOT pseudoaneurysm; locoregional embolization for metastatic pancreatic cancer; embolization for asymptomatic persistent sciatic artery; endovascular treatment of spinal dural arteriovenous fistula; genicular artery embolization for osteoarthritis knee pain; hemorrhoidal embolization using HydroPearl microspheres; HydroPearl microspheres for lower-extremity AVMs; bariatric arterial embolization; middle meningeal artery embolization for chronic subdural hematoma; paraumbilical vein coil embolization for hepatic encephalopathy; preoperative embolization for carotid body tumor resection; preoperative inferior mesenteric artery embolization to prevent type II endoleak; and prostatic arterial embolization for BPH.
Specific devices and techniques are identified as lacking sufficient evidence. The policy highlights that HydroPearl microspheres have not been established as effective for hemorrhoidal embolization or for lower-extremity AVMs, and that paraumbilical vein coil embolization for hepatic encephalopathy is supported only by extremely limited case reporting and is therefore considered investigational.
Several indications are described as having uncertain net health benefit pending further research. For example, middle meningeal artery embolization (MMAE) has pooled RCT evidence suggesting reduced recurrence in some cohorts but uncertainty remains regarding effects on functional outcomes and mortality; long-term benefits of prostatic arterial embolization (PAE) remain uncertain with higher retreatment rates reported in some trials; and hemorrhoidal embolization has encouraging case series but insufficient evidence to confirm improved health outcomes.
Providers may perform services that are determined to be not medically necessary or non-covered only after verifying member benefits and obtaining documented informed consent. The member must be informed of the non-covered status and must agree in writing in advance to assume financial responsibility; otherwise the provider risks claim denial and may not bill the member for the service.
Coding and Key Thresholds
| No codes listed |
| No codes listed |
| 37242 | Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquired arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms) |
| 37243 | Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction |
Provider Actions, Prior Authorization, and Documentation Requirements
Obtain prior authorization for Medicare Advantage; recommend web-based preauth for Commercial
Prior authorization is required for Medicare Advantage Plans and is recommended for Commercial Products via the web‑based tool for participating providers.
Preauthorization may be required for select embolization indications
Preauthorization may be required for certain embolization indications described in the policy, including lower gastrointestinal bleeding, portal vein embolization prior to hepatectomy, and tumor (preoperative) embolization—check payer preauthorization rules for these indications.
Authorize and document medical necessity for CPT 37242 and 37243
Prior authorization may be required per the payer’s Prior Authorization of Services, Treatments or Procedures policy; CPT codes 37242 and 37243 are listed as medically necessary when the policy’s medical criteria are met and may be subject to review.
Verify benefits and eligibility before providing service
Verify member benefits and eligibility with the provider call center and by reviewing the member’s subscriber or employer agreement prior to scheduling services.
- Benefits and eligibility are determined by the member’s subscriber agreement, member certificate, and/or the employer agreement.
- Call the provider call center for member‑specific coverage determinations.
Document failure of conservative therapy when required
For select covered indications (e.g., geniculate artery embolization), document prior failure of conservative therapies as required by the policy before proceeding with embolization.
- Example conservative therapies: ice, immobilization, compression, saline lavage, corticosteroid instillation, selective COX‑2 inhibitors.
- Document angiographic evidence of synovial hypervascularity when applicable.
Use angiographic embolization for massive lower GI bleeding (vasopressin alternative)
For massive lower GI bleeding, angiographic (super‑selective transcatheter) embolization is an accepted primary treatment option; vasopressin infusion is noted as an alternative with comparable efficacy.
- Massive bleeding defined as transfusion requirement of 4 units of blood or more in 24 hours.
- Super‑selective transcatheter embolization with microcoils is the main endovascular treatment option.
Document prior treatments and rationale when requesting PAE
When considering prostatic arterial embolization (PAE), document prior treatments and the clinical rationale—RCTs and systematic reviews compare PAE to TURP and medical therapy and report variable retreatment rates.
- Record prior medical therapy and duration (policy references ≥3 months failure for some prostatic hematuria indications).
- Include rationale if PAE is selected given evidence of higher retreatment in some trials.
Submit clinical documentation and imaging to support medical necessity
Provide clinical documentation supporting the specific covered indication (one of the policy’s listed medical criteria) and relevant imaging or endoscopy results (for example, localization of bleeding) to support medical necessity.
- Include imaging/endoscopy reports that localize the pathology (e.g., bleeding site on bleeding scan or colonoscopy).
- Attach prior treatment records when conservative therapy failure is required.
Document FLR assessment and surgical timing for PVE
For portal vein embolization (PVE) performed preoperatively, document assessment of the future liver remnant (FLR) and the surgical timing plan, noting that surgeons generally wait 3 to 6 weeks post‑PVE before resection.
- Include objective FLR measurements and the planned hepatic resection timeline.
- State that PVE is intended because FLR is marginal and would otherwise preclude curative hepatectomy.
Support CPT 37242/37243 coding with indication-specific documentation
When billing CPT 37242 or 37243, ensure documentation supports that the policy’s medical criteria are met and that the procedure performed corresponds to the code description (arterial other than hemorrhage/tumor vs for tumors/organ ischemia/infarction).
- Link the selected CPT code to the documented indication and intra‑procedural findings.
- Provide operative and imaging reports that justify the chosen code.
Confirm eligibility and document informed consent for non‑covered services
Verify member benefits and eligibility with the provider call center and document informed consent if the member agrees to proceed with a service that is not covered or not medically necessary and will be self‑pay.
- Obtain written member agreement in advance if proceeding with non‑covered services at member expense.
- Record counseling and consent in the medical record.
Avoid offering/ billing insufficient‑evidence procedures without trial context or authorization
Procedures and indications identified in the policy as having insufficient evidence are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products and may be denied if submitted without meeting an applicable covered criterion.
- Examples listed include embolization for locoregional metastatic pancreatic cancer, hemorrhoidal embolization, bariatric arterial embolization, MMAE in certain cohorts, and others as enumerated in the policy.
- Do not submit claims for these indications without documentation meeting medical necessity criteria or explicit prior authorization acceptance.
Provide locoregional mPDAC embolization only within clinical trials
Locoregional embolization for metastatic pancreatic ductal adenocarcinoma (mPDAC) should be provided only in the context of an experimental clinical trial; offering it outside a trial may lead to denial.
- Systematic review authors recommend locoregional treatments for mPDAC only within experimental trials until high‑quality RCTs are available.
Risk of denial if CPT 37242/37243 criteria not met
Procedures that do not meet the policy’s medical criteria for CPT codes 37242 and 37243 may be denied on medical necessity review.
- Ensure the submitted documentation explicitly demonstrates how the case meets the listed medical criteria for the selected CPT code.
Do not bill members for non‑covered services without documented written consent
Services determined to be not medically necessary or that are non‑covered benefits may result in denial; do not charge the member unless they have been informed and have agreed in writing to self‑pay in advance.
- Document that the member was informed of non‑coverage and obtained signed agreement prior to providing the service at their expense.
- Refer to participation agreements for billing obligations.
Background
Vascular embolization is an endovascular procedure that deliberately occludes blood vessels without open surgery to control bleeding, treat tumors, reduce size of vascular malformations, or redirect blood flow. It can be performed using coils, particles, liquid embolic agents, or plugs and may be applied to a wide range of clinical problems when less invasive approaches are preferred or when surgical options are not feasible.
Definitions and Terminology
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.